Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer
Up to 70% of patients with non-muscle-invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the United States. The purpose of this study was to test the performance of a multiplex urinary biomarker assay for the monitoring of voided urine for r...
Gespeichert in:
| Veröffentlicht in: | Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2014-07, Vol.23 (7), p.1340-1345 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1345 |
|---|---|
| container_issue | 7 |
| container_start_page | 1340 |
| container_title | Cancer epidemiology, biomarkers & prevention |
| container_volume | 23 |
| creator | ROSSER, Charles J MYRON CHANG YUNFENG DAI ROSS, Shanti MENGUAL, Lourdes ALCARAZ, Antonio GOODISON, Steve |
| description | Up to 70% of patients with non-muscle-invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the United States. The purpose of this study was to test the performance of a multiplex urinary biomarker assay for the monitoring of voided urine for recurrent bladder cancer.
This retrospective, multicenter study included a total of 125 subjects with a history of bladder cancer. Voided urine specimens were collected before procedure from these subjects (53 with confirmed tumor recurrence and 72 with confirmed non-tumor recurrence) for analysis. A prediction rule generated from the performance characteristics of 10 single biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SERPINE1, and SDC1) was measured using ELISA. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values (e.g., sensitivity and specificity).
The combination of all 10 biomarkers outperformed any single biomarker with a calculated AUROC for the diagnostic panel of 0.904 [95% confidence interval (CI), 0.853-0.956]. The multiplex assay achieved an overall sensitivity of 79% and specificity of 88% for recurrent bladder cancer and significantly outperformed the Urovysion cytogenetic assay (sensitivity 42%, specificity 94%) and voided urinary cytology (sensitivity 33%, specificity 90%).
A diagnostic panel of 10 urinary biomarkers that accurately detects primary bladder cancer also performs well for the detection of recurrent bladder cancer.
The identification of a reliable urine-based surveillance and detection assay would be of benefit to both patients and the healthcare system. |
| doi_str_mv | 10.1158/1055-9965.EPI-14-0035 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4317370</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>24714076</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-e7d233dbf2ff9342fbfef5426b0cb2523f2b20f159435a8d16c3e8abf9543b1b3</originalsourceid><addsrcrecordid>eNpVkF1LwzAUhoMobk5_gpIbLzvz2bQ3gs6pg4lD3HVI0sRVu2aknbB_b8o-1KscyPO-5_AAcInREGOe3WDEeZLnKR-OZ5MEswQhyo9AH3OaJUJwfhznPdMDZ03ziRASOeenoEeYwAyJtA9e5qGsVdjAWfCtLWt4X_qlCl82wJmqbQWdD7BdWPhgW2va0tfQO_hmzToEW7fwvlJFEeGRqo0N5-DEqaqxF7t3AOaP4_fRczJ9fZqM7qaJYQy3iRUFobTQjjiXU0acdtZxRlKNjCacUEc0QQ7znFGusgKnhtpMaZdzRjXWdABut72rtV7awsRLgqrkKpTx9o30qpT_f-pyIT_8t2QUCypQLODbAhN80wTrDlmMZOdXdu5k505GvxIz2fmNuau_iw-pvdAIXO8A1RhVuRC9lM0vl6UpFQTRH6NrhUA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>ROSSER, Charles J ; MYRON CHANG ; YUNFENG DAI ; ROSS, Shanti ; MENGUAL, Lourdes ; ALCARAZ, Antonio ; GOODISON, Steve</creator><creatorcontrib>ROSSER, Charles J ; MYRON CHANG ; YUNFENG DAI ; ROSS, Shanti ; MENGUAL, Lourdes ; ALCARAZ, Antonio ; GOODISON, Steve</creatorcontrib><description>Up to 70% of patients with non-muscle-invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the United States. The purpose of this study was to test the performance of a multiplex urinary biomarker assay for the monitoring of voided urine for recurrent bladder cancer.
This retrospective, multicenter study included a total of 125 subjects with a history of bladder cancer. Voided urine specimens were collected before procedure from these subjects (53 with confirmed tumor recurrence and 72 with confirmed non-tumor recurrence) for analysis. A prediction rule generated from the performance characteristics of 10 single biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SERPINE1, and SDC1) was measured using ELISA. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values (e.g., sensitivity and specificity).
The combination of all 10 biomarkers outperformed any single biomarker with a calculated AUROC for the diagnostic panel of 0.904 [95% confidence interval (CI), 0.853-0.956]. The multiplex assay achieved an overall sensitivity of 79% and specificity of 88% for recurrent bladder cancer and significantly outperformed the Urovysion cytogenetic assay (sensitivity 42%, specificity 94%) and voided urinary cytology (sensitivity 33%, specificity 90%).
A diagnostic panel of 10 urinary biomarkers that accurately detects primary bladder cancer also performs well for the detection of recurrent bladder cancer.
The identification of a reliable urine-based surveillance and detection assay would be of benefit to both patients and the healthcare system.</description><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.EPI-14-0035</identifier><identifier>PMID: 24714076</identifier><identifier>CODEN: CEBPE4</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Area Under Curve ; Biological and medical sciences ; Biomarkers, Tumor - urine ; Carcinoma, Transitional Cell - pathology ; Carcinoma, Transitional Cell - urine ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasm Recurrence, Local - urine ; Nephrology. Urinary tract diseases ; Retrospective Studies ; ROC Curve ; Tumors ; Tumors of the urinary system ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - urine ; Urinary system involvement in other diseases. Miscellaneous ; Urinary tract. Prostate gland</subject><ispartof>Cancer epidemiology, biomarkers & prevention, 2014-07, Vol.23 (7), p.1340-1345</ispartof><rights>2015 INIST-CNRS</rights><rights>2014 American Association for Cancer Research.</rights><rights>2014 American Association for Cancer Research. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-e7d233dbf2ff9342fbfef5426b0cb2523f2b20f159435a8d16c3e8abf9543b1b3</citedby><cites>FETCH-LOGICAL-c441t-e7d233dbf2ff9342fbfef5426b0cb2523f2b20f159435a8d16c3e8abf9543b1b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3354,27922,27923</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28663720$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24714076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ROSSER, Charles J</creatorcontrib><creatorcontrib>MYRON CHANG</creatorcontrib><creatorcontrib>YUNFENG DAI</creatorcontrib><creatorcontrib>ROSS, Shanti</creatorcontrib><creatorcontrib>MENGUAL, Lourdes</creatorcontrib><creatorcontrib>ALCARAZ, Antonio</creatorcontrib><creatorcontrib>GOODISON, Steve</creatorcontrib><title>Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer</title><title>Cancer epidemiology, biomarkers & prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>Up to 70% of patients with non-muscle-invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the United States. The purpose of this study was to test the performance of a multiplex urinary biomarker assay for the monitoring of voided urine for recurrent bladder cancer.
This retrospective, multicenter study included a total of 125 subjects with a history of bladder cancer. Voided urine specimens were collected before procedure from these subjects (53 with confirmed tumor recurrence and 72 with confirmed non-tumor recurrence) for analysis. A prediction rule generated from the performance characteristics of 10 single biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SERPINE1, and SDC1) was measured using ELISA. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values (e.g., sensitivity and specificity).
The combination of all 10 biomarkers outperformed any single biomarker with a calculated AUROC for the diagnostic panel of 0.904 [95% confidence interval (CI), 0.853-0.956]. The multiplex assay achieved an overall sensitivity of 79% and specificity of 88% for recurrent bladder cancer and significantly outperformed the Urovysion cytogenetic assay (sensitivity 42%, specificity 94%) and voided urinary cytology (sensitivity 33%, specificity 90%).
A diagnostic panel of 10 urinary biomarkers that accurately detects primary bladder cancer also performs well for the detection of recurrent bladder cancer.
The identification of a reliable urine-based surveillance and detection assay would be of benefit to both patients and the healthcare system.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - urine</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Carcinoma, Transitional Cell - urine</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasm Recurrence, Local - urine</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Retrospective Studies</subject><subject>ROC Curve</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - urine</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><subject>Urinary tract. Prostate gland</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkF1LwzAUhoMobk5_gpIbLzvz2bQ3gs6pg4lD3HVI0sRVu2aknbB_b8o-1KscyPO-5_AAcInREGOe3WDEeZLnKR-OZ5MEswQhyo9AH3OaJUJwfhznPdMDZ03ziRASOeenoEeYwAyJtA9e5qGsVdjAWfCtLWt4X_qlCl82wJmqbQWdD7BdWPhgW2va0tfQO_hmzToEW7fwvlJFEeGRqo0N5-DEqaqxF7t3AOaP4_fRczJ9fZqM7qaJYQy3iRUFobTQjjiXU0acdtZxRlKNjCacUEc0QQ7znFGusgKnhtpMaZdzRjXWdABut72rtV7awsRLgqrkKpTx9o30qpT_f-pyIT_8t2QUCypQLODbAhN80wTrDlmMZOdXdu5k505GvxIz2fmNuau_iw-pvdAIXO8A1RhVuRC9lM0vl6UpFQTRH6NrhUA</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>ROSSER, Charles J</creator><creator>MYRON CHANG</creator><creator>YUNFENG DAI</creator><creator>ROSS, Shanti</creator><creator>MENGUAL, Lourdes</creator><creator>ALCARAZ, Antonio</creator><creator>GOODISON, Steve</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20140701</creationdate><title>Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer</title><author>ROSSER, Charles J ; MYRON CHANG ; YUNFENG DAI ; ROSS, Shanti ; MENGUAL, Lourdes ; ALCARAZ, Antonio ; GOODISON, Steve</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-e7d233dbf2ff9342fbfef5426b0cb2523f2b20f159435a8d16c3e8abf9543b1b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - urine</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Carcinoma, Transitional Cell - urine</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasm Recurrence, Local - urine</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Retrospective Studies</topic><topic>ROC Curve</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - urine</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ROSSER, Charles J</creatorcontrib><creatorcontrib>MYRON CHANG</creatorcontrib><creatorcontrib>YUNFENG DAI</creatorcontrib><creatorcontrib>ROSS, Shanti</creatorcontrib><creatorcontrib>MENGUAL, Lourdes</creatorcontrib><creatorcontrib>ALCARAZ, Antonio</creatorcontrib><creatorcontrib>GOODISON, Steve</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ROSSER, Charles J</au><au>MYRON CHANG</au><au>YUNFENG DAI</au><au>ROSS, Shanti</au><au>MENGUAL, Lourdes</au><au>ALCARAZ, Antonio</au><au>GOODISON, Steve</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer</atitle><jtitle>Cancer epidemiology, biomarkers & prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>23</volume><issue>7</issue><spage>1340</spage><epage>1345</epage><pages>1340-1345</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><coden>CEBPE4</coden><abstract>Up to 70% of patients with non-muscle-invasive bladder cancer (NMIBC) experience disease recurrence, making it one of the most prevalent cancers in the United States. The purpose of this study was to test the performance of a multiplex urinary biomarker assay for the monitoring of voided urine for recurrent bladder cancer.
This retrospective, multicenter study included a total of 125 subjects with a history of bladder cancer. Voided urine specimens were collected before procedure from these subjects (53 with confirmed tumor recurrence and 72 with confirmed non-tumor recurrence) for analysis. A prediction rule generated from the performance characteristics of 10 single biomarkers (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, APOE, SERPINE1, and SDC1) was measured using ELISA. The diagnostic performance of the biomarker panel was assessed using receiver operator curves (ROC) and descriptive statistical values (e.g., sensitivity and specificity).
The combination of all 10 biomarkers outperformed any single biomarker with a calculated AUROC for the diagnostic panel of 0.904 [95% confidence interval (CI), 0.853-0.956]. The multiplex assay achieved an overall sensitivity of 79% and specificity of 88% for recurrent bladder cancer and significantly outperformed the Urovysion cytogenetic assay (sensitivity 42%, specificity 94%) and voided urinary cytology (sensitivity 33%, specificity 90%).
A diagnostic panel of 10 urinary biomarkers that accurately detects primary bladder cancer also performs well for the detection of recurrent bladder cancer.
The identification of a reliable urine-based surveillance and detection assay would be of benefit to both patients and the healthcare system.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>24714076</pmid><doi>10.1158/1055-9965.EPI-14-0035</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1055-9965 |
| ispartof | Cancer epidemiology, biomarkers & prevention, 2014-07, Vol.23 (7), p.1340-1345 |
| issn | 1055-9965 1538-7755 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4317370 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Area Under Curve Biological and medical sciences Biomarkers, Tumor - urine Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - urine Enzyme-Linked Immunosorbent Assay Female Humans Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Recurrence, Local - urine Nephrology. Urinary tract diseases Retrospective Studies ROC Curve Tumors Tumors of the urinary system Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - urine Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland |
| title | Urinary Protein Biomarker Panel for the Detection of Recurrent Bladder Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T19%3A51%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Urinary%20Protein%20Biomarker%20Panel%20for%20the%20Detection%20of%20Recurrent%20Bladder%20Cancer&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=ROSSER,%20Charles%20J&rft.date=2014-07-01&rft.volume=23&rft.issue=7&rft.spage=1340&rft.epage=1345&rft.pages=1340-1345&rft.issn=1055-9965&rft.eissn=1538-7755&rft.coden=CEBPE4&rft_id=info:doi/10.1158/1055-9965.EPI-14-0035&rft_dat=%3Cpubmed_cross%3E24714076%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/24714076&rfr_iscdi=true |